For how we live.
Among privately insured patients, 63% with IVF coverage had a baby within 2.5 years versus 53% without. The gap was driven mostly by covered patients starting more cycles — not a higher success rate per cycle.
Injecting one sperm into each egg was meant for severe male-factor cases, yet clinics now use it widely. Pooling six randomised trials found no live-birth advantage over standard IVF when sperm is not the problem.
A European trial stopped early for futility: clinical pregnancy occurred in 15.7% of women given transdermal testosterone before IVF and 14.9% given placebo. The trial was funded by Ferring.
In a 4,376-woman trial across 24 Chinese centres, natural-cycle embryo transfer gave the same healthy-live-birth rate as a programmed hormone regimen, with less pre-eclampsia and postpartum haemorrhage.
Two systematic reviews point the same way: for the pill, IUDs, implants and most methods, about 8 in 10 women conceive within a year of stopping — similar to using no method at all.
Two randomised trials tested whether thyroid-hormone tablets help women who carry thyroid antibodies but have normal thyroid function and a history of miscarriage or infertility. Live-birth rates did not move.
The 2023 global guideline puts lifestyle first for everyone, letrozole first for fertility, and the pill for cycles and excess hair — while rating much of its own evidence low to moderate quality.
In two large clinics, the live birth rate per woman who returned to use her eggs was around 39-50% under 35 or 38, but far lower for older women — and most women who froze never came back to use them.
In modern couples timing intercourse, an estimated 18% of women aged 35-39 failed to conceive within a year — not one in three. The most alarming figures come from models, not from watching real couples try.
Using genetic variants as instruments, researchers found exercise and wellbeing lowered risk of PCOS, endometriosis and menstrual disorders, while screen time and mood swings raised it.
An 876-participant double-blind trial across 24 Chinese fertility centres nearly doubled serum 25-OHD in women with PCOS. Live births were 52.0% against 50.2% on placebo.
A double-blind trial randomised 750 women with polycystic ovary syndrome to one drug or the other. Letrozole produced more live births and more ovulation — and is now the guideline's first choice for fertility.